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Discussion
In ML patients with comparable pretransplant performance sta-
tus, there were no statistical differences in complications, engraft-
ment, cell count yield, cell viability, days of apheresis, platelet
transfusions, or mobilization regimen between older and younger
patients receiving autografts. However, younger patients appeared
to require greater RBC blood product support (p0.05). Our data
suggests that older ML patients with good performance status can
be treated with autologous stem cell treatment strategies compa-
rable to those developed for younger patients.
Results
Variables/Age
Group <60 (N23) >60 p-value
Age (years) 43.9 {38.7, 49.1} 62.9 {60.5, 65.3} <.0001
Days of
Apheresis 2.87 {2.33, 3.41} 2.22 {1.48, 2.97} 0.18
CD 34 yield 5.06 {3.91, 6.20} 6.01 {3.37, 8.65} 0.28
Viability Day 1 83.8 {80.6, 87.0} 87.8 {83.4, 92.1} 0.15
Viability Day 2 84.5 {80.0, 88.2} 83.6 {74.8, 92.4} 0.76
Viability Day 3 82.9 {76.7, 89.0} 80.3 {53.5, 107} 0.57
Days to ANC
Engraftment 12.7 {11.6, 13.8} 12.0 {10.3, 13.7} 0.47
Days to PLT
Engraftment 15.5 {14.0, 17.0} 15.2 {13.6, 16.8} 0.75
Number of
PLT
Transfusions 3.17 {2.14, 4.21} 3.00 {1.41, 4.58} 0.95
Number of
RBC
Transfusions 3.96 {2.74, 5.18} 2.11 {1.35, 3.09} 0.05
Mobilization
Regimen
(%G) 57 67 0.70
Death <100
Days 4.4 0 1.00
Mucositis II-IV
<30 Days 30.4 0 0.15
Sepsis <30
Days 8.7 22.2 0.56
Pneumonia
<30 Days 8.7 0 1.00
Karnofsky
Score 97 99 1.00
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OUTCOME WITH A THIOTEPA CONTAINING REGIMEN AND AUTOLO-
GOUS HSCT IN PATIENTS WITH NHL
Cumpston, A.D.1, Bulian, D.A.1, Kanate, A.1, Weisenborn, R.1,
Bunner, P.1, Visweshwar, N.I.1, Craig, M.1, Ericson, S.G.1 1West
Virginia University Hospitals, Morgantown, WV.
Introduction: High dose chemotherapy and autologous hemato-
poietic stem cell rescue offers patients with advanced non-hodgkin
lymphoma (NHL) a chance for long-term survival and cure. The role
of thiotepa in this approach is still unknown, and little data with
long-term follow-up has been published. The best chemotherapy
regimen prior to stem cell infusion for patients with NHL remains
unknown.
Methods/Outcome: Twenty-nine patients with advanced NHL
were treated with high dose VP-16, cyclophosphamide, and thio-
tepa followed by autologous HSC rescue from 1993-2006. Median
age was 53 (range 27-69), and all patients except 2 were beyond
CR1. Overall survival and disease-free survival were 76% and 66%
respectively at a median follow-up of 44 months. Five patients
relapsed, with a median time to relapse of 150 days after transplant
(range 82-300 days). Treatment related mortality was 10% (3/29);
all 3 died from infectious complications before day 50. One patient
developed treatment-related myelodysplasia.
Conclusion: An aggressive preparative regimen for autologous
HSCT containing thiotepa offers patients a signiﬁcant chance for
long-term disease-free survival. However, caution is recommended
due to early infectious complications.
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IMMUNE MOBILIZATION OF AUTOLOGOUS PERIPHERAL BLOOD PRO-
GENITOR CELLS: IL-2 WITH GM-CSF AND G-CSF RESULTS IN EFFEC-
TIVE MOBILIZATION WITHOUT DELAY IN ENGRAFTMENT
Hill, J.M.1, Wu, J.-Y.1, Webber, S.1, Sharlin, O.1, Ernstoff, M.S.1,
Szczepiorkowski, Z.M.1, Meehan, K.P.1 1Dartmouth Hitchcock Medical
Center, Lebanon, NH.
We initiated an immune mobilization trial in an attempt to mobilize
cytotoxic effector cells, along with CD34 hematopoietic progenitor
cells. A Prospective Phase I trial was initiated using dose escalation of
IL-2, in combination with GM-CSF and G-CSF. IL-2 began on Day
0 and continued as a daily SQ injection for 11 days. On Day 7,
GM-CSF (7.5 mcg/kg/d) and G-CSF (5 mcg/kg/d) were initiated for
5 days (Days 7-11). On Day 11, leukapheresis was started if the
peripheral blood CD34 cell count was 5 cells/mcl. The endpoint
of collection was 3 106 CD34 cells/kg. After collection, patients
received melphalan (200 mg/m2) followed by infusion of cryopre-
served stem cells. Post-transplant GM-CSF began on Day 5 and
terminated once the ANC reached 5000 cells/mcl. To date, 10 pa-
tients have been treated (myeloma, n 9; NHL, n 1) and 9 patients
are evaluable. Dose escalation of IL-2 continues since the MTD has
not been reached. The ﬁrst two dose levels of IL-2 have been well
tolerated: Dose Level 1 (6 105 IU/m2/d; n 6 pts); and Dose Level
2 (1  106 IU/m2/d; n  3 pts). One patient has completed Dose
Level 3 (1.5  105 IU/m2/d) without difﬁculty. One patient (NHL)
was removed from the study due to progressive disease. The remain-
ing 9 patients completed the regimen. Toxicities have been mild and
have included Grade 2 fever (n1) on Dose Level 2. All patients were
successfully mobilized. The median number of CD34 cells/kg and
MNC/kg collected were 3.4  106 (range 2.8 – 4.4  106/kg) and
9.5  108 (range 0.4 – 1.7  109), respectively. Two large volume
leukaphereses were required (median; range 1 – 3). Following trans-
plant, the ANC recovered on Day 13 (median; range: 10 – 14 d) and
platelets recovered on Day 12 (median; range 0 – 13 d). These
preliminary results demonstrate that immune mobilization and col-
lection of an adequate number of hematopoietic progenitor cells is
feasible without suppression of hematopoiesis. Toxicities are minimal
but the MTD of IL-2 has not yet been reached. Post-transplant
engraftment is not delayed. As patient accrual continues, we are
currently evaluating the qualitative and quantitative components of
the collected cells, including Th1 vs. Th2 cells and the types of
dendritic cells mobilized, while evaluating lymphocyte recovery fol-
lowing transplant.
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AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (AUTO-HCT)
IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RESULTS OF A SYSTEM-
ATIC REVIEW
Kharfan-Dabaja, M.A.1, Kumar, A.1, Behera, M.1, Field, T.1,
Ayala, E.1, Perez, L.1, Fernandez, H.1, Anasetti, C.1, Djulbegovic, B.1
1H. Lee Mofﬁtt Cancer Center and Research Institute, Tampa, FL.
Background: Despite improvements in responses, CLL remains
incurable with conventional chemotherapy (CC). About 1/3 of pa-
tients are  60 yrs, and are offered experimental therapies including
high-dose chemotherapy (HDT) and auto-HCT. The objective of
this study is to present the totality of the evidence by conducting a
systematic review to assess the efﬁcacy of auto-HCT in the treatment
of CLL. Methods: A systematic search of the literature was per-
formed using MEDLINE databases (1966- Sep 12, 2006) and hand-
search of references. Included studies were prospective-randomized,
non-randomized or single-arm trials. Data were extracted on primary
outcomes (response rate (RR), overall survival (OS), progression-free
survival (PFS) etc.). Results: Our search identiﬁed altogether 82
publications. Only 8 met our pre-determined inclusion criteria (ta-
ble1). In this cohort of 8 trials, 2 trials were funded by public/
government sources, 2 by private foundations, 1 was funded jointly by
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